Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-11-21 00:00:00 ET · period of report 2025-11-20 · accession 0001601360-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-21 | 2025-11-20 | ARQT | Gilbert Halley E | Dir | S - Sale+OE | $27.55 | -16.5K | 22.1K | -43% | -$455.5K |
| D | 2025-11-21 | 2025-11-20 | ARQT | Gilbert Halley E | Dir | M - OptEx | $7.51 | +12.2K | 38.7K | +46% | +$91.8K |
| D | 2025-11-21 | 2025-11-20 | ARQT | Gilbert Halley E | Dir | M - OptEx | $0.00 | -12.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-20 | S | D | 16,532 | $27.55 | 22,123 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $27.32 to $27.72, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-11-20 | M | A | 12,220 | $7.51 | 38,655 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2025-11-20 | M | D | 12,220 | $0.00 | 0 | D | $7.51 · — to 2033-05-31 | 12,220 Common Stock | (F1) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. |